Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: A phase II trial of efficacy and toxicity

Anne Kanard, Aminah Jatoi, Rene Castillo, Susan Geyer, Thomas K. Schulz, Tom R. Fitch, Kendrith M. Rowland, Suresh Nair, James E. Krook, John W. Kugler, Jeffrey S. Brindle, John C. Michalak, James A. Mailliard, Martin Wiesenfeld, Carl G. Kardinal, Larry P. Ebbert, Harold E. Windschitl, Loren K. Tschetter, Edith Perez

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Abstract

Purpose: Before now oral vinorelbine has not yet been tested in a cohort of elderly, advanced non-small cell lung cancer patients, even though the intravenous form of this drug provides a reasonable therapeutic option for this group. This trial was conducted to determine the tumor response rate and toxicity profile of oral vinorelbine in advanced non-small cell lung cancer patients ≥65 years of age. Patients and methods: Fifty-eight evaluable patients ≥65 years of age with advanced non-small cell lung cancer were enrolled. Median age was 73 years (range: 65-87). The Eastern Cooperative Oncology Group (ECOG) performance score was 0, 1, or 2 in 29, 59, and 12% of patients, respectively. All patients had adequate organ function. Oral vinorelbine 60mg/m2 per week was prescribed weekly as first-line therapy. Results: Two patients manifested a confirmed tumor response, yielding a response rate of 3.4% (95% confidence interval (CI): 0.4, 11.9%). There were no complete responses. Median progression-free survival was 3.5 months (95% CI: 2.2, 5.4 months), and median overall survival was 7.5 months (95% CI: 5.0, 12 months). There were five deaths, one of which might have been treatment-related, and there were 10 grade 4 events. Conclusions: Oral vinorelbine, as prescribed in this trial, provides minimal activity in the treatment of advanced non-small cell lung cancer in patients ≥65 years of age.

Original languageEnglish (US)
Pages (from-to)345-353
Number of pages9
JournalLung Cancer
Volume43
Issue number3
DOIs
StatePublished - Mar 2004

Keywords

  • Elderly
  • Lung cancer
  • Oral chemotherapy
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: A phase II trial of efficacy and toxicity'. Together they form a unique fingerprint.

Cite this